Additionally, we clarified the immunomodulatory role of PLCG2 in inducing tumor immunosuppressive microenvironment and thus enhancing tumor immune escape and explored the efficacy of the synergistic therapy with knockdown of PLCG2 and ICB therapy, which identified PLCG2 as a potentially effective biomarker and a valuable target for the early diagnosis and individualized therapy of CRC (Figure 10G). The gene discussed is PLCG2; the disease is colorectal carcinoma.